Member Info for stu485

Read your post back again.

The most ridiculous I’ve ever seen !

…then great news!

There’s absolutely nothing indicated so far with regard the independent analysis.

Either of us equally entitled to our opinion .

Time will tell !

AIMO

The Hat,
I’m glad that at least one other shared my concern!!

Where we disagree, 1&2 completed does not change the overall independent analysis one way or the other as it’s a check on the process not the outcome.
Should there be a problem there’s nothing to suggest it will quickly be resolved, it might be and equally it might not!

AIMO

The evidence is in the previous RNS if you read it properly!!

A third part now has to confirm the quality. There’s the risk.
Making your 100% statement, factually incorrect.

But hey, who cares about facts !!!

AIMO

The next RNS will be, problems with pre-qual runs and a requirement for more than the minimum!

That’s what I’m expecting.

AIMI

When does fully funded mean, we need more funds !?

Putting that uncomfortable question aside,
the bigger question all should be asking is, what can you achieve with £4m !!!!
My guess, cover the general costs (nothing new) to try and fix problems yet to be announced on the road to IND.

Posters here have bravely admitted to have been fooled by this boards hype yet again. That will NOT change.
Any attempts for a measured and reasoned view are drowned out by the “golden ticket”BS brigade.

AIMO

I’ll be adding after what i expect an announcement of more pre-qual work required before IND.
My view on the probability of the above transpiring…high!
AIMO

JFH,

In the past you’ve demonstrated particular insight.
May I ask;
What time frame do you expect for Cart-T analytical results?
Any chance there may be more runs required over the min required 3 performed?
I’m sure surprising for some but I’m getting closer to adding a little and want to time as best i can.

I’ve found through experience that it literally pays to question any gaps or apparent gaps within company communication.
May prove stupid on this issue or may not.

No question or suspicions regarding the original delay, that was clearly communicated by the company.

The question was simply regarding the lack of further update. It appears there is none!

Than you for clarification.

I’d have thought an on-line pre IND meeting announcement would then have been made and update of outcome in RNS reach but not going to let that thought spoil the day !

JFH ?

I can’t believe you wouldn’t already know ?

If no reply I’ll take P’s advise email ask myself.

Genuine question.
What happened?
Did it go ahead and was there an update ?

“Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration ("FDA") that the proposed pre-Investigational New Drug ("pre-IND") meeting relating to the Company's lead product candidate Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") is to be deferred until May 2022 “

Yep, agreed.
Just offering a more reasoned explanation to that of the more fanciful posters who are probably unaware of the important differences in type of RNS.

Many have questioned the SP fall back,
considering it “over done” and blame individual disruptive posters and/or MM’s.

Maybe they should ponder that not even the company Nomad considered the recent CBR news significant enough for a material change in SP and hence the RNS was only an RNS reach.

I’m not suggesting the recent news was not potential progress, just that the CBR value was already to a great extent already baked in the SP.

The fall back being market recognition of the same .
AIMO
Ps Now happy with patent position.

Chris,
Thanks for your thoughts.
“we must be advised it’s not progressing before April, otherwise the relevant “market sensitive news” regulations would be offended ? “

If JFH says, yes the above is correct, then all good with me.
On the other hand even with his well earned rest considered, if he cant type a single word answer “yes” then even more suspicious!

JFH
Ok , understood.
So no news is good news in regards to CBR full patent application.

Your take on it, we must be advised it’s not progressing before April, otherwise the relevant “market sensitive news” regulations would be offended ?

He wouldn’t waste time on confirming a patent on the most important (recent stock price considered) development!?

Something not adding up in my opinion!

JFH ??

JFH

So I presume you’d be expecting an RNS to announce the patent soon then ?

“But Stu, to answer your question, Vlad is married to a Intellectual Property expert, I am confident they wont forget to file the full patent application, but by all means email them to remind them the date is close approaching”.